SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Nabriva Therapeutics AG (NBRV)

NBRV RSS Feed
Add NBRV Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 6/3/2016 8:04:16 PM - Followers: 2 - Board type: Free - Posts Today: 0
Nabriva Therapeutics AG
Leberstrasse 20
Vienna, 1110
Austria
Phone: 43 1 740 93 0
Fax: 43 1 740 93 1900
Website: http://www.nabriva.com


Nabriva Therapeutics AG, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which has completed a Phase II clinical trial for acute bacterial skin and skin structure infections. The company is developing intravenous and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia; and intends to develop lefamulin for additional indications other than pneumonia. It is also developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics AG in 2007. Nabriva Therapeutics AG was incorporated in 2005 and is headquartered in Vienna, Austria.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NBRV
Current Price
Volume:
Bid Ask Day's Range
SureTrader
NBRV News: Report of Foreign Issuer (6-k) 11/29/2016 04:37:53 PM
NBRV News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 11/29/2016 04:30:23 PM
NBRV News: Report of Foreign Issuer (6-k) 11/29/2016 04:18:53 PM
NBRV News: Nabriva Announces Terms of Rights Offering 11/29/2016 04:00:00 PM
NBRV News: Report of Foreign Issuer (6-k) 11/22/2016 09:00:40 AM
PostSubject
#1   NBRV bearish 7.38 stocktrademan 06/03/16 08:04:16 PM
PostSubject